Get the Stockscreener App
9.75
0.31%
-0.03
After Hours:
9.75
Anika Therapeutics Inc stock is traded at $9.75, with a volume of 57,296.
It is down -0.31% in the last 24 hours and up +3.72% over the past month.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
See More
Previous Close:
$9.78
Open:
$9.72
24h Volume:
57,296
Relative Volume:
0.52
Market Cap:
$140.58M
Revenue:
$166.88M
Net Income/Loss:
$-74.18M
P/E Ratio:
-1.9231
EPS:
-5.07
Net Cash Flow:
$1.14M
1W Performance:
-2.60%
1M Performance:
+3.72%
6M Performance:
-32.90%
1Y Performance:
-43.02%
1-Day Range:
$9.72
$9.93
1-Week Range:
$9.585
$10.17
52-Week Range:
$7.8701
$18.37
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
9.75 | 141.01M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | B. Riley Securities | Buy |
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
Anika Therapeutics (NASDAQ:ANIK) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
What is the fair value estimate for Anika Therapeutics Inc. (AKP) stock in 20252025 EndofYear Setup & Technical Pattern Based Signals - newser.com
What dividend safety rating applies to Anika Therapeutics Inc. (AKP) stockTrade Ideas & Scalable Portfolio Growth Methods - newser.com
Key metrics from Anika Therapeutics Inc.’s quarterly data2025 Winners & Losers & Verified Technical Signals - newser.com
Is Anika Therapeutics Inc. stock supported by strong cash flows2025 Winners & Losers & Weekly Setup with High ROI Potential - newser.com
Why Anika Therapeutics Inc. stock could rally in 2025Weekly Profit Analysis & Breakout Confirmation Alerts - newser.com
Does Anika Therapeutics Inc. show high probability of reboundJuly 2025 EndofMonth & Safe Entry Trade Reports - newser.com
Why Anika Therapeutics Inc. stock could outperform in 2025Bear Alert & Low Risk High Win Rate Stock Picks - newser.com
Detecting support and resistance levels for Anika Therapeutics Inc.Inflation Watch & Long Hold Capital Preservation Plans - newser.com
Is Anika Therapeutics Inc. stock positioned for long term growthTrade Ideas & Risk Managed Investment Entry Signals - newser.com
Strategies to average down on Anika Therapeutics Inc.2025 Year in Review & Free High Accuracy Swing Entry Alerts - newser.com
How to escape a deep drawdown in Anika Therapeutics Inc.2025 Growth vs Value & Smart Allocation Stock Reports - newser.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) is a favorite amongst institutional investors who own 60% - Yahoo Finance
Using AI based signals to follow Anika Therapeutics Inc.Quarterly Investment Review & Stepwise Entry/Exit Trade Alerts - newser.com
Can Anika Therapeutics Inc. stock sustain revenue growth2025 Momentum Check & Real-Time Price Movement Reports - Fundação Cultural do Pará
Will Anika Therapeutics Inc. (AKP) stock benefit from sector leadershipMarket Performance Report & Daily Technical Forecast Reports - Fundação Cultural do Pará
Can Anika Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Macro Moves & Fast Gain Swing Alerts - Fundação Cultural do Pará
Is Anika Therapeutics Inc. stock attractive for growth ETFsWeekly Gains Summary & Long-Term Safe Investment Ideas - Fundação Cultural do Pará
Anika Therapeutics’ Integrity Implant System Study: A Market Game Changer? - TipRanks
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anika Therapeutics Inc Stock (ANIK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):